NCT05360056

Continuous Glucose Monitoring Following Hospital Discharge

Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 108 (actual)
• Sponsor: Kathleen Dungan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DEVICE	DexCom G6	Wearable continuous glucose monitor

Timeline

• Start date: 2022-04-26
• Primary completion: 2024-08-31
• Completion: 2025-12-01
• First posted: 2022-05-04
• Last updated: 2025-12-09
• Results posted: 2025-12-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated device study